Skip to content
Faron, etusivu
Releases and publications
Careers
Contact Information
Search for:
LANGUAGE
English
Suomi
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Analysts
Analysis
Outlook
Share and shareholders
Share information
Shareholders
Share monitor
Management ownership and transactions
Option plans and Warrants
Public offering 2024
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
For Patients
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Analysts
Analysis
Outlook
Share and shareholders
Share information
Shareholders
Share monitor
Management ownership and transactions
Option plans and Warrants
Public offering 2024
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
For Patients
Releases and publications
Careers
Contact Information
Search for:
LANGUAGE
English
Suomi
releases and publications
Category
All
Company announcements
Press releases
Managers' transactions
Flagging notifications
Year
All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
03.04.2025
Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million
Regulatory
27.03.2025
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress
21.03.2025
Board Changes
Regulatory
21.03.2025
Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM
Regulatory
20.03.2025
Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected
Regulatory
03.03.2025
Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS
Regulatory
28.02.2025
NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING
Regulatory
27.02.2025
Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS)
Regulatory
27.02.2025
Faron Pharmaceuticals Ltd’s Annual Report 2024 published
Regulatory
27.02.2025
Faron’s Financial Statement Release 1 January to 31 December 2024
Regulatory
Next
Back to top
